Price-sensitive information on issuers of securities up to 08/02/2020

BAYER AKTIENGESELLSCHAFT

from 01/07/1988 to 11/03/2025

The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish

• • 18/11/2019
  • 12:50
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Not intended for U.S. and UK Media -Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint
  • Register number: 283749
• • 08/11/2019
  • 08:54
  • BAYER AKTIENGESELLSCHAFT
  • Fixed income issues
  • NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN - Bayer refinances 1.75 billion euro hybrid bond
  • Register number: 283442
• • 04/11/2019
  • 14:53
  • BAYER AKTIENGESELLSCHAFT
  • Transmissions and purchases of capital undertakings
  • Bayer completes sale of Dr. Scholl’s™ brand to Yellow Wood Partners
  • Register number: 283260
• • 30/10/2019
  • 08:23
  • BAYER AKTIENGESELLSCHAFT
  • Strategic plans, profit forecasts and presentations
  • Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
  • Register number: 283025
• • 30/10/2019
  • 08:17
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Bayer: Q3 2019 Analyst and Investor Briefing
  • Register number: 283021
• • 17/10/2019
  • 11:57
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Restatements of Q1-Q4 2018 and Q1-Q2 2019 due to presentation of Animal Health & Currenta as discontinued operations
  • Register number: 282642
• • 16/10/2019
  • 11:23
  • BAYER AKTIENGESELLSCHAFT
  • Information on P&L
  • Bayer: Q3 2019 Publication Schedule
  • Register number: 282606
• • 14/10/2019
  • 16:09
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Not intended for U.S. and UK Media - U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
  • Register number: 282563
• • 01/10/2019
  • 15:25
  • BAYER AKTIENGESELLSCHAFT
  • Composition of the board of directors
  • Ertharin Cousin to become member of Bayer AG Supervisory Board
  • Register number: 282206
• • 30/09/2019
  • 08:37
  • BAYER AKTIENGESELLSCHAFT
  • R&D: new licenses, patents and registered trademarks
  • Not intended for U.S. and UK Media -Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
  • Register number: 282122